Vytrus Biotech registers EUR 2.5m revenue in 1H24, up 28% over 1H23
Vytrus Biotech registra una facturación de EUR 2,5m en el primer semestre de 2024, un 28% más que en el mismo período de 2023
Intel ID : 396267
Relevant Documents
| Notice / Relevant Fact | 16 Jul 2024 | Vytrus_Biotech_Hecho_Relevante_2024.pdf | ES |
|
| Intel ID | 396267 | |
| Value | EUR 2,50m | |
| Native Currency | Euro (EUR) | |
|
Financial Data - Vytrus Biotech
(31 Dec 2021) |
Revenue: EUR 3,60m EBITDA: EUR 1,01m Net Debt: EUR 8,83m People: 27 |
|
| Date |
 |
|
| Country |  |
|
| Geography | |
|
| Subsector (Old TTR Sectors) |
|
|
| Primary Subsector (TTRSC) |
15.04.01 Cosmetics & Perfumes (Primary) 15 Consumer Products & Services / 15.04 Consumer Nondurables |
|
| Secondary Subsectors (TTRSC) |
30.01.01 Biopharmaceuticals 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals 30.01.03 Pharmaceutical R&D, Manufacturing & Distribution 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
|
| Type |
|
|
| Intel Grade |
|
|
| Source |
|
|
| Tags | |
Target
| Name |
|
||
| Subsector (Old TTR Sectors) |
|
||
| Primary Sector (TTRSC) |
15.04.01 Cosmetics & Perfumes 15 Consumer Products & Services / 15.04 Consumer Nondurables |
||
| Secondary Sectors (TTRSC) |
30.01.01 Biopharmaceuticals 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals 30.01.03 Pharmaceutical R&D, Manufacturing & Distribution 30 Healthcare / 30.01 Biotechnology & Pharmaceuticals |
||
| Country |
|
||
| Website |
|
||
| Description |
|
Radar
| Date | Title | Type | Intel Grade | Country | Subsector | ||
|
|
|
|
|
|
|
|
Legend:
Verified: Confirmed as a party to an active or possible transaction.
Potential: Unconfirmed as a party to an active or possible transaction.
Retained: Confirmed as “Retained” with a general or specific mandate.
Prospect: Advisory “Prospect” in discussions with or pitching services to possible client.
Transactional data is continuously updated by the research team and therefore is subject to change.